Luciferase-GFP Spike (SARS-CoV-2) Pseudotyped Lentivirus
|Catalog#||Unit||Unit Price (USD)||Actions|
|SV11||5 x 20 µl, concentrated||$1,950.00||Add to Cart|
- Safe - BSL2 conditions appliable
- Multiple choices of 3rd-generation lentivector reporter(e.g., GFP, Luciferase) to meet your requirement
- Ideal for COVID-19 research, such as virus infectivity study, drug screen (neutralization assays), vaccine
- Vaccine development for prevention of infection by SARS-CoV-2 virus
- Studying the efficacy and mechanism of neutralizing antibodies against SARS-CoV-2 virus
- Development of anti-coronavirus therapeutic agents
- Studying the mechanism of virus-receptor interaction
The Spike (SARS-CoV-2) pseudotyped lentivirus was produced with SARS-CoV-2 Spike protein as the envelope glycoprotein instead of vesicular stomatitis G (VSV-G) envelope glycoprotein. These pseudoviruses also contain Luciferase gene driven by CMV promoter and GFPT2A-puro driven by EF1α promoter, therefore, the spike-mediated cell entry can be conveniently quantified by luciferase activity and visualized under a fluorescent microscope. The Spike (SARS-CoV-2) pseudotyped lentivirus can be used for studying basic mechanisms and drug development including measuring the activity of neutralizing antibody against SARS-CoV-2, and screening anti-CoV2 drugs in a Biosafety Level 2 facility
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Infection of SARS-CoV-2 to human cells is initiated by the binding of its Spike protein to ACE2 (angiotensin converting enzyme 2), a homodimer receptor, on the surface of some human cells, particularly those in the respiratory tract. The Spike protein promotes attachment of ACE2 to the subunit S1 and its RBD (Receptor Binding Domain) region, facilitates fusion of the viral and cellular membrane releasing the virus core into the cell. Therefore, drugs targeting the interaction between the Spike protein of SARSCoV-2 and ACE2 may offer protection against the viral infection. Due to the highly transmissible and pathogenic nature of SARS-CoV-2, handling of live virus requires a biosafety level 3 (BSL3) containment. In order to extend this capability to BSL-2, a high titer pseudotype virus is needed to meet such requirement that effectively replaces the need for the live SARS-CoV-2.
- Crawford, K.H.D., et al., Viruses, 2020. 12(5).
|Product Name||Luciferase-GFP Spike (SARS-CoV-2) Pseudotyped Lentivirus|
Dry Ice - Overnight
|Storage and Stability||
Store at -80°C
For Research Use Only. Not for use in diagnostic or therapeutic procedures.